Neumora Therapeutics Future Growth
Future criteria checks 0/6
Neumora Therapeutics is forecast to grow earnings and revenue by 14.1% and 79.9% per annum respectively. EPS is expected to grow by 19.5% per annum. Return on equity is forecast to be -45.6% in 3 years.
Key information
14.1%
Earnings growth rate
19.5%
EPS growth rate
| Pharmaceuticals earnings growth | 23.9% |
| Revenue growth rate | 79.9% |
| Future return on equity | -45.6% |
| Analyst coverage | Good |
| Last updated | 25 Nov 2024 |
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 37 | -302 | -232 | -233 | 7 |
| 12/31/2025 | N/A | -281 | -210 | -217 | 8 |
| 12/31/2024 | N/A | -253 | -212 | -205 | 8 |
| 9/30/2024 | N/A | -294 | -189 | -184 | N/A |
| 6/30/2024 | N/A | -274 | -204 | -198 | N/A |
| 3/31/2024 | N/A | -254 | -179 | -173 | N/A |
| 12/31/2023 | N/A | -236 | -168 | -163 | N/A |
| 9/30/2023 | N/A | -155 | -142 | -142 | N/A |
| 6/30/2023 | N/A | -132 | -120 | -120 | N/A |
| 3/31/2023 | N/A | -123 | -116 | -116 | N/A |
| 12/31/2022 | N/A | -131 | -128 | -115 | N/A |
| 9/30/2022 | N/A | -130 | -128 | -114 | N/A |
| 6/30/2022 | N/A | -278 | -119 | -105 | N/A |
| 3/31/2022 | N/A | -265 | -106 | -92 | N/A |
| 12/31/2021 | N/A | -237 | -76 | -75 | N/A |
| 9/30/2021 | N/A | -230 | -65 | -63 | N/A |
| 12/31/2020 | N/A | -99 | -28 | -27 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NMRA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NMRA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NMRA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NMRA is forecast to have no revenue next year.
High Growth Revenue: NMRA is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NMRA is forecast to be unprofitable in 3 years.